Drugs / SIPAGLADENANT
Trials 8 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT04342273 | Mar → Sep 2020 | Parkinson disease | Kyowa Kirin, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04190654 | Nov 2019 → Mar 2020 | — | Kyowa Kirin, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04070495 | Aug → Nov 2019 | Parkinson disease | Kyowa Kirin, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04147910 | Aug → Oct 2019 | — | Kyowa Kirin, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03970798 | May → Jul 2019 | Parkinson disease | Kyowa Kirin, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03830528 | Feb → Oct 2019 | Parkinson disease | Kyowa Kirin, Inc. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT03703570 | Sep 2018 → Apr 2020 | Parkinson disease | Kyowa Kirin, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02939391 | Sep 2016 → Nov 2017 | Parkinson disease | Kyowa Kirin, Inc. | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SIPAGLADENANT | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314441 ↗ |
| Known as | KW-6356 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03830528 ↗ |
| Action | Inhibit | “KW-6356 is a novel selective adenosine A2A receptor antagonist/inverse agonist.” PMID 37948832 ↗ Oct 2023 |
| Modality | Small molecule | — CHEMBL5314441 ↗ |
| Route | Oral | “6 mg/day) orally administered as monotherapy for 12 weeks” PMID 37948832 ↗ Oct 2023 |
| Target | ADORA2A | “Adenosine A2a receptor inverse agonist” CHEMBL5314441 ↗ |